NCT04364776 2023-09-28
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
Fondazione IRCCS Policlinico San Matteo di Pavia
Unknown
Clinical Trials
4 trialsNCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT04359199 2023-02-10
QUASAR
University of California, San Diego
Unknown
NCT04672759 2020-12-17
A Real-world Study of Durvalumab for Lung Cancer in China
Peking Union Medical College Hospital
Unknown